Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

Source: 
BioPharma Dive
snippet: 

The pharma set the average cost of it and Biogen’s newly approved medicine Leqembi to $26,500 per year.